Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST02 + interleukin-2
- Development stage
- Unknown
- Lead developer
- Biosyngen
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BST02 is an autologous, cryopreserved tumor-infiltrating lymphocyte (TIL) cell therapy developed by Biosyngen for the treatment of liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma. The therapeutic process involves harvesting lymphocytes from a patient's tumor tissue, expanding them ex vivo, and reinfusing them following lymphodepletion chemotherapy with cyclophosphamide and fludarabine. The regimen includes the administration of interleukin-2 (IL-2) to support the expansion and persistence of the infused TILs within the patient. BST02 is designed to overcome logistical barriers associated with traditional TIL therapies through cryopreservation and aims to utilize lower doses of IL-2 to improve tolerability. It is the first TIL therapy for liver cancer to enter clinical trials globally.
- Other names
- BST02 + IL-2BST02 + interleukin-2
Beyond the preview
Go deeper on BST02 + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST02 + interleukin-2.